Treatment of patients with psoriasis and/or psoriatic arthritis and concomitant hepatitis C
infection remains difficult. Except for cyclosporine, other drugs have proved unacceptable …

Background Adalimumab, a fully human, anti‐TNFα monoclonal antibody has been shown
to be effective for moderate‐to‐severe psoriasis in clinical trial setting. However, only a …

HIV/AIDS is listed among the relative contraindication for anti‑TNF‑α treatment [2] and HIV
infection is usually ruled out prior to initiation TNF‑α therapy. However, high levels of TNF‑α …

AIM To evaluate the outcomes in biological treatment and quality of life of psoriatic patients
with chronic hepatitis C (CHC) treated with new Direct-Acting Antiviral agents (DAAs) …

Introduction There are no strong data regarding the treatment with biologics (especially for
the most recent anti-IL-17 and anti-IL-23 drugs) of patients with psoriasis and concomitant …

Simple Summary Psoriasis is a chronic multisystem inflammatory disease associated with a
wide range of comorbidities including cardiovascular disease, hypertension, diabetes …

Background: Monotherapy with TNF‐α inhibitors does not always produce a sufficient
response in psoriasis patients. Combinations of TNF‐α antagonists such as adalimumab …

Background This phase 3 trial is the first to evaluate the efficacy and safety of treatment with
the systemic TNF‐α inhibitor, adalimumab, for Chinese patients with moderate‐to‐severe …

Background No consensus exists regarding the optimal laboratory screening for hepatitis B
infection that should be performed before initiating therapy with tumor necrosis factor-alfa …

Treatment of patients with psoriasis and concomitant hepatitis-C virus (HCV) infection poses
a therapeutic challenge because most systemic drugs are associated with potential …